News

Valneva announced that it intends to delist from the Vienna Stock Exchange (VSE) in order to focus on the best capital markets for life science...

Read more

The agreement grants Gilead exclusive rights to HOOKIPA’s TheraT® and VaxWave® investigational arenavirus-based immunization technologies for the...

Read more

Valneva announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its chikungunya vaccine candidate, VLA1553. ...

Read more

In January 2019, the new Managing Director of the Vienna BioCenter Core Facilities GmbH, Daniele Soroldoni, has started his work. Welcome!

Read more

The Vienna Biocenter Summer School provides a unique opportunity for approx. 28 undergraduate students to work side-by-side with leading researchers...

Read more

Strategic collaboration agreement with Sandoz to develop digital anti-infectives platform.

Read more

Valneva today announced the initiation of the Phase 2 Clinical Development for its leading, unique Lyme disease vaccine candidate VLA15.

Read more

The clinical trial will be conducted at approximately 35 centers worldwide and will include a total of 150 male and female patients.

Read more

Congrats to the VBCF Plant Sciences Facility! Their FFG FuE Infrastrukturförderung application for a multi-sensor and multi-approach high-throughput...

Read more

Vienna BioCenter launches a state-of-the-art website that lives up to the innovation and dynamism of this vibrant life science cluster.

Read more